PER

0.00%

10.0¢ percheron therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-114

First 114 Last

Share
Profile

Follow
itsagas

13,342 Posts.

1424

21/04/23

21:22

Post #: 67404102
Share

Originally posted by arjay: ↑

Plenty of tension here when it comes to the SP ...and yes its valid..

So, what do we have at the moment and how much is it worth is a million $$ question and I guess that would be the case of investing in ANP ...I mean hold or buy more or if someone sees value somewhere else ....

Well we do have a fantastic data which is recognised by plenty of experts around the world...most important is our PI...prof Voit

And to get this data has it taken over 5 years ..so obviously we are 5 years head of anyone starting now...

We are getting no where...feels like that at the moment...

Why ...obvious delays...

Well nothing from AF on deals and even if one was in discussions we wouldnt have a clue unless it's signed on paper...

Anyways we all know all the above...

What is the team now...CG , AF...
GT and ND have done an excellent job so far with the science / drug and no question about that...

Deals take time that's the reality......and it can take a very long time ..and most times it never happens....so what will AF bring or can get is a question ..

Now just an example...even if Sarepta offered $50m for Half of EU....would you accept??

Obviously big NO...

Reality is no one offers $50m to a company whose MC is $50m...well it hasn't happened before ( EVER ) to my knowledge, so I have serious doubts .....

Even if it was offered...most holders here including myself would be jumping up and down....and go nuts as all are expecting $1.2 b deal that Sarepta got...

Reality is we do not get that at the stage we are...unless we are the luckiest in the world to get $100 or $200m upfront...and other in milestones...

Well that's won't happen that's the reality , so for me deal is not happening at the moment...the gap may be too big that's the problem...its not that there is no interest in the drug.... it's the agreement getting the deal together...

So what do we have after this ..Long Covid..

There is no interest in Covid IMO...and deal for that would have been done by now as it can be as little as $2-5m to get in bed together...so IMO it's not coming...

All big numbers / deals will come into the game if we get the trial up and running asap and that's the key...that's where the interest is from around the world ...that's where the $$ is waiting...that's where the interest is from the parents of DMD effected kids...

Now all our other games live ODD , Market exclusivity etc will come into picture once we are half way through the trials....

All eyes will be on the results mid 2024....and I believe that's the only thing that will deliver true $$...

Everyone knows , we do not have enough funds to even complete the existing trial, forget about MD and others getting wages....so in this case everyone may want to take advantage whether it's deal or anything else... getting a new CEO is also not easy....

New CEO will need to get $$ first before he even starts tbh....is my opinion...and that's a big job in the current market...

So we need a CEO who is a believer and achiever.....

I just have one more thing in my mind...CG wouldn't want to f this up after a fantastic career ...so there is my hope .

Anything AF brings is a bonus IMO...Yes we have story and results , but getting those $$ is the real game...

All the delays in the trial is really not making any sense...is 3rd part calling all the cards?? Dunno...

Market is not confident with trial starting soon, $$ needed, no team.... No communication from mgt...too many unknowns and most impt is past delivery time frames is all against the existing mgt...

I think better oppurtunities elsewhere...hence some may me moving funds...

Any thoughts??

All above is IMO...Dyor

Expand

We have been told many times that $$$ are not needed ATM.
So let’s put that to bed
We have been told many times that the 4 countries involved in the DMD trial will be approved on a staggered timeline… Turkey approved.. so we wait for the other 3…When Bulgaria is approved we’re on our way because UK and Australia I don’t expect any problems ..
So you see folks.. everyone is worried about nothing..Our primary object is to get the Tox study and the DMD trial on its way..
We wait $$

ANP Price at posting: 7.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

There are more pages in this discussion • 4 more messages in this thread...

First 114 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $90.15M

Open	High	Low	Value	Volume
10.5¢	10.5¢	10.0¢	$47.27K	463.5K

Buyers (Bids)

No.	Vol.	Price($)
3	319942	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	86442	3

View Market Depth

No.	Vol.	Price($)
3	319942	0.100
3	113179	0.099
1	13000	0.098
2	130927	0.097
1	10004	0.096

Price($)	Vol.	No.
0.105	86442	3
0.110	290000	4
0.115	601850	5
0.120	275642	8
0.125	65000	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

PER (ASX) Chart

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-114

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-114

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News